Biogen
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- 7.5K
- Market Cap
- $29.6B
- Website
- https://www.biogen.com
- Introduction
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)
- Conditions
- Interventions
- First Posted Date
- 2015-09-21
- Last Posted Date
- 2019-11-22
- Lead Sponsor
- Biogen
- Target Recruit Count
- 20
- Registration Number
- NCT02555215
- Locations
- 🇹🇷
Research Site, Ankara, Turkey
Study to Evaluate the Interaction Between a Drug and CNV1014802 in Healthy Subjects
- First Posted Date
- 2015-09-16
- Last Posted Date
- 2017-10-16
- Lead Sponsor
- Biogen
- Target Recruit Count
- 36
- Registration Number
- NCT02551497
- Locations
- 🇬🇧
Research Site, Nottingham, United Kingdom
Systemic Sclerosis Clinical and Biomarker Study
- Conditions
- First Posted Date
- 2015-08-21
- Last Posted Date
- 2015-11-01
- Lead Sponsor
- Biogen
- Registration Number
- NCT02531009
Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).
- Conditions
- Interventions
- First Posted Date
- 2015-08-18
- Last Posted Date
- 2019-06-27
- Lead Sponsor
- Biogen
- Target Recruit Count
- 218
- Registration Number
- NCT02525874
- Locations
- 🇹🇷
Research Site, Umuttepe, Kocaeli, Turkey
Single-Dose Study of a New Formulation of BIIB061
- First Posted Date
- 2015-08-13
- Last Posted Date
- 2015-09-07
- Lead Sponsor
- Biogen
- Target Recruit Count
- 8
- Registration Number
- NCT02521545
- Locations
- 🇺🇸
Research Site, Madison, Wisconsin, United States
Tecfidera Lymphocyte Chart Review
- Conditions
- First Posted Date
- 2015-08-10
- Last Posted Date
- 2016-08-26
- Lead Sponsor
- Biogen
- Target Recruit Count
- 483
- Registration Number
- NCT02519413
- Locations
- 🇺🇸
Research site, Homewood, Alabama, United States
🇺🇸Research Site, Milwaukee, Wisconsin, United States
221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease
- First Posted Date
- 2015-06-29
- Last Posted Date
- 2021-09-02
- Lead Sponsor
- Biogen
- Target Recruit Count
- 1643
- Registration Number
- NCT02484547
- Locations
- 🇺🇸
Lehigh Center for Clinical Research, LLC, Allentown, Pennsylvania, United States
🇺🇸Syrentis Clinical Research, Santa Ana, California, United States
🇺🇸Hattiesburg Clinic, PA, Hattiesburg, Mississippi, United States
221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease
- First Posted Date
- 2015-06-23
- Last Posted Date
- 2021-09-02
- Lead Sponsor
- Biogen
- Target Recruit Count
- 1653
- Registration Number
- NCT02477800
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇮🇹Azienda Ospedaliero Universitaria Ospedali Riuniti, Torrette Di Ancona, Ancona, Italy
🇵🇹Centro Hospitalar e Universitário de Coimbra E.P.E, Coimbra, Portugal
Study to Explore the Onset of Efficacy on Magnetic Resonance Disease Activity of BG00012 (Dimethyl Fumarate) in Patients With Relapsing remitTing Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2015-06-16
- Last Posted Date
- 2015-12-28
- Lead Sponsor
- Biogen
- Registration Number
- NCT02472938
Tecfidera and the Gut Microbiota
- Conditions
- Interventions
- First Posted Date
- 2015-06-15
- Last Posted Date
- 2021-09-05
- Lead Sponsor
- Biogen
- Target Recruit Count
- 36
- Registration Number
- NCT02471560
- Locations
- 🇳🇴
Research site, Stavanger, Norway
🇳🇴Research Site, Lillehammer, Norway